M-L Dahl

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

Leif Bertilsson, JA Carrillo, M-L Dahl et al. · British Journal of Clinical Pharmacology · 1994 · 308 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.

Ming Chang, Gunnel Tybring, M-L Dahl et al. · British Journal of Clinical Pharmacology · 1995 · 184 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy

Anna‐Karin Hamberg, M-L Dahl, Martina Barban et al. · Clinical Pharmacology & Therapeutics · 2007 · 142 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin

M-L Dahl, Jonas Cederberg, MO Karlsson et al. · Clinical Pharmacology & Therapeutics · 2007 · 94 citations

Medicine, Pharmacokinetics, Pharmacology +14

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

R A Kiivet, Adrián LLerena, M-L Dahl et al. · British Journal of Clinical Pharmacology · 1995 · 59 citations · Full text

Pharmacy, Pharmacotherapy, Psychiatry +11